Chemed (CHE) BofA Securities 2025 Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
BofA Securities 2025 Healthcare Conference summary
2 Mar, 2026Medicare Cap Management and Industry Outlook
Medicare cap has been a constant since 1983, with ongoing monitoring and forecasting at site level.
Investments in analytics and go-to-market strategies enable proactive management of cap exposure.
Recent growth rates have been intentionally moderated to maintain a sustainable Medicare cap cushion.
Regional reimbursement differences, especially in California and Florida, are factored into planning.
Transparent communication about cap cushion changes is prioritized, with no fundamental business model shifts.
Strategic Response to Regulatory and Market Changes
Regular engagement with MedPAC and industry groups to advocate for cap policy updates.
Policy realignment, rather than abolition, is seen as a practical improvement.
Medicare cap is viewed as a deterrent to bad actors, but not a barrier to sustainable growth.
Workforce retention and clinical capacity growth are key drivers, independent of cap policy.
Mission-focused care and open formulary support talent attraction and partner relationships.
Acquisition and Expansion Strategy
Recent acquisition of Covenant in Florida signals openness to strategic deals, especially in CON states.
Expansion into new counties and states, including applications in North Carolina and other states.
Positive integration of Covenant has enhanced reputation among nonprofit providers.
Proactive outreach to potential acquisition targets has increased, leveraging strong balance sheet.
Relationship-based approach and capital flexibility support further growth opportunities.
Latest events from Chemed
- 2025 revenue rose 4.1%, but earnings fell; 2026 guidance anticipates stronger H2 growth.CHE
Q4 20253 Mar 2026 - Q2 2024 featured robust VITAS growth, Roto-Rooter declines, and raised full-year guidance.CHE
Q2 20242 Feb 2026 - Expecting high single-digit revenue and 10% EPS growth, with robust M&A and expansion plans.CHE
Jefferies 2024 Global Healthcare Conference31 Jan 2026 - VITAS growth offset Roto-Rooter softness, driving higher revenue and raised 2024 EPS guidance.CHE
Q3 202417 Jan 2026 - VITAS posts strong growth while Roto-Rooter pivots strategy amid rising competition.CHE
UBS Global Healthcare Conference 202414 Jan 2026 - Strong hospice growth and stable margins expected, with disciplined M&A and Roto-Rooter recovery underway.CHE
Bank of America Home Care Conference11 Jan 2026 - VITAS is accelerating growth and margins, targeting 8%-10% volume gains and strategic expansion.CHE
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Hospice and Roto-Rooter show steady growth, with capital focused on acquisitions and buybacks.CHE
Oppenheimer 35th Annual Health Care MedTech and Services Conference26 Dec 2025 - VITAS drove record growth, offsetting Roto-Rooter softness; 2025 outlook remains positive.CHE
Q4 202423 Dec 2025